Vir Biotechnology Cash Flow Statement
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vir Biotechnology free cash flow
In fiscal 2025, Vir Biotechnology generated -$391.8 million of operating cash flow and spent $4.8 million on capital expenditures. That left free cash flow of -$396.6 million, a free-cash-flow margin of -578.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Vir Biotechnology cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -437.99M | -521.96M | -615.12M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income growth (YoY) | — | — | -219.25% | -2.41% | — | — | — | — | — |
| Depreciation & Amortization | 11.68M | 14.56M | 19.45M | 6.78M | 5.28M | 4.40M | 3.29M | 1.62M | 255.00K |
| Stock-Based Compensation | 49.07M | 78.46M | 111.32M | 102.08M | 83.78M | 27.60M | 8.72M | 5.05M | 4.78M |
| Change in Working Capital | -7.64M | -60.88M | -17.00K | 725.74M | -682.69M | -8.93M | 2.61M | 9.49M | 2.65M |
| Operating Cash Flow | -391.78M | -446.35M | -778.78M | 1.66B | -47.59M | -190.94M | -129.63M | -94.10M | -66.38M |
| Capital Expenditures | -4.83M | -7.30M | -21.57M | -68.01M | -21.82M | -6.55M | -8.94M | -8.19M | -2.74M |
| Investing Cash Flow | 310.37M | 499.37M | 164.63M | -1.19B | -140.81M | -9.86M | -256.16M | -60.44M | -29.99M |
| Financing Cash Flow | 3.79M | 4.39M | 7.48M | 34.76M | 100.33M | 529.47M | 449.24M | 24.98M | 271.18M |
| Net Change in Cash | -77.63M | 57.40M | -606.68M | 504.55M | -88.07M | 328.67M | 63.45M | -129.56M | 174.81M |
| Free Cash Flow | -396.61M | -453.65M | -800.36M | 1.60B | -69.41M | -197.49M | -138.57M | -102.29M | -69.12M |
This table shows 9 annual periods of Vir Biotechnology's cash flow statement, from FY 2025 back to FY 2017, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VIR's reporting calendar. What is a cash flow statement?